Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success

Core Insights - Therma Bright Inc. announces a significant milestone with its portfolio company Inretio, as Inretio's Preva® ischemic stroke clot removal device successfully completes its third human trial, indicating its potential to transform stroke and blood clot treatment [2][3][7] Company Overview - Therma Bright Inc. is a developer and investment partner in advanced diagnostic and medical device technologies, focusing on innovative solutions for critical healthcare challenges [8] Product Innovation - The Preva® device represents a major advancement in thrombectomy procedures, designed to restore blood flow in ischemic stroke patients effectively, even when traditional treatments fail [3][4] - The device utilizes a patented solution that minimizes the risk of embolization and reduces the need for repeated maneuvers during the procedure [4] Market Potential - The global coronary stents market is projected to exceed USD 4.8 billion by 2029, presenting a growth opportunity for Inretio's Preva® solution and Therma Bright's investment [6] - The demand for advanced clot removal solutions is increasing, positioning Therma Bright's investment in Inretio to potentially yield significant returns as the technology progresses [7]